ATRC AtriCure, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1323885 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.8%
TTM net income YoY151.7%
TTM EPS YoY150.8%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—
Margins
Gross margin76.7%
Operating margin2.9%
Net margin2.5%
FCF margin9.0%
EBITDA margin4.9%
Returns
ROE2.9%
ROA2.2%
ROIC (approx.)3.9%
Asset turnover0.87x
Leverage & solvency
Liabilities / assets25.7%
Debt / equity0.11x
Current ratio4.33x
Interest coverage2.95x
Cash quality & payout
Operating cash flow / net income4.61x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue2.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $154.45M | $153.60M | $141.25M | $140.50M | $134.27M | $136.14M | $123.62M | $124.28M |
| Cost of revenue | $35.10M | $34.98M | $31.94M | $35.16M | $32.94M | $34.66M | $30.99M | $31.66M |
| Gross profit | $119.35M | $118.63M | $109.31M | $105.34M | $101.33M | $101.48M | $92.63M | $92.62M |
| R&D expense | $32.12M | $26.40M | $24.23M | $24.50M | $22.89M | $29.28M | $22.53M | $34.96M |
| SG&A expense | $82.88M | $82.56M | $84.55M | $78.34M | $78.23M | $78.39M | $76.05M | $72.19M |
| Operating income | $4.35M | $9.66M | $526,000 | $2.49M | $208,000 | -$6.19M | -$5.95M | -$14.52M |
| Interest expense | $1.61M | $1.32M | $1.34M | $1.50M | $1.47M | $1.49M | $1.42M | $1.45M |
| Pretax income | $4.02M | $9.43M | $394,000 | $2.36M | -$86,000 | -$5.93M | -$6.51M | -$15.30M |
| Income tax | -$47,000 | $471,000 | $286,000 | $604,000 | $181,000 | $261,000 | $239,000 | $266,000 |
| Net income | $4.06M | $8.96M | $108,000 | $1.76M | -$267,000 | -$6.19M | -$6.75M | -$15.57M |
| EBITDA | $7.45M | $12.59M | $3.42M | $5.49M | $3.27M | -$3.13M | -$2.98M | -$11.58M |
| EPS (basic) | 0.08 | 0.18 | 0.00 | — | -0.01 | -0.13 | -0.14 | — |
| EPS (diluted) | 0.08 | 0.18 | 0.00 | — | -0.01 | -0.13 | -0.14 | — |
| Weighted avg. shares (diluted) | 49.83M | 48.87M | 49.05M | — | 47.92M | 47.72M | 47.39M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $187.03M | $167.79M | $146.16M | $167.43M | $147.87M | $117.80M | $99.89M | $122.72M |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Receivables | $76.13M | $79.98M | $71.31M | $66.65M | $62.98M | $66.00M | $63.32M | $60.34M |
| Inventory | $87.31M | $83.92M | $81.14M | $78.49M | $78.95M | $76.34M | $74.91M | $75.33M |
| Current assets | $363.39M | $345.53M | $313.69M | $322.52M | $301.11M | $271.26M | $251.48M | $267.83M |
| PP&E, net | $66.67M | $42.42M | $39.74M | $39.12M | $39.55M | $40.68M | $41.24M | $41.66M |
| Goodwill | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M |
| Intangibles | $40.88M | $43.26M | $45.64M | $48.03M | $50.14M | $52.25M | $54.36M | $56.47M |
| Total assets | $717.54M | $676.64M | $643.99M | $654.18M | $635.44M | $608.85M | $591.63M | $609.33M |
| Current liabilities | $83.97M | $81.92M | $73.19M | $81.52M | $77.84M | $68.84M | $61.22M | $73.42M |
| Short-term debt | — | — | — | — | — | — | — | $2.81M |
| Long-term debt | $61.00M | $61.00M | $61.00M | $61.87M | $61.87M | $61.87M | $61.87M | $61.87M |
| Total debt | $61.00M | $61.00M | $61.00M | $61.87M | $61.87M | $61.87M | $61.87M | $64.67M |
| Total liabilities | $184.31M | $160.21M | $152.29M | $162.24M | $158.94M | $144.36M | $137.01M | $148.36M |
| Shareholders' equity | $533.22M | $516.43M | $491.69M | $491.94M | $476.51M | $464.49M | $454.62M | $460.97M |
| Net debt | -$126.03M | -$106.79M | -$85.17M | -$105.56M | -$86.00M | -$55.93M | -$38.02M | -$58.05M |
| Shares outstanding | 50.91M | 50.86M | 50.63M | 49.79M | 49.71M | 49.69M | 49.49M | 48.87M |
| Cash flow statement | ||||||||
| Operating cash flow | $30.32M | $22.19M | -$4.00M | $20.03M | $26.72M | $21.62M | -$11.03M | $5.84M |
| Capital expenditure | $6.39M | $3.77M | $3.85M | $1.60M | $2.60M | $2.66M | $2.18M | $2.69M |
| Free cash flow | $23.93M | $18.43M | -$7.85M | $18.43M | $24.11M | $18.95M | -$13.21M | $3.14M |
| Investing cash flow | -$10.89M | -$3.77M | -$3.85M | -$2.60M | -$2.60M | -$7.66M | -$1.68M | -$14.69M |
| Financing cash flow | -$26,000 | $3.26M | -$13.26M | $2.10M | $5.98M | $3.42M | -$10.32M | $1.74M |
| Depreciation & amortization | $3.09M | $2.92M | $2.89M | $3.00M | $3.06M | $3.06M | $2.97M | $2.94M |
| Stock-based compensation | $12.48M | $12.31M | $11.27M | $11.26M | $12.42M | $11.37M | $9.63M | $10.38M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.